Complications of Herpes Simplex Virus Infection – Evidence‑Based Summary
Neurological Complications
Central Nervous System
HSV‑2 meningitis typically presents with headache, photophobia, fever, meningismus, and a CSF profile showing lymphocytic pleocytosis, mildly elevated protein, and normal glucose. The CDC notes this presentation in its clinical guidance. 1
Recurrent lymphocytic meningitis is attributable to HSV‑2 in 78–84 % of cases, representing a notable sequela of genital HSV‑2 infection. 1
Peripheral Nervous System
No cited peripheral‑nervous‑system complications met the inclusion criteria (all were marked “ignore ref”).
Systemic and Visceral Complications
Pneumonitis secondary to HSV infection requires hospitalization and intravenous acyclovir therapy. This recommendation is supported by CDC MMWR reports. 2
HSV‑related hepatitis is a recognized visceral manifestation that also mandates intravenous antiviral treatment. 2
In HIV‑infected individuals, genital or perianal HSV outbreaks are often prolonged, severe, painful, and may present atypically, necessitating a high index of suspicion. 2
Acyclovir resistance occurs more frequently in HIV‑infected patients with prolonged antiviral exposure, underscoring the need for resistance monitoring. 2
Neonatal Complications
Neonatal HSV infection presents in three patterns:
Among neonates with disseminated or CNS disease, a vesicular rash is absent in about 40 % of cases, which can delay diagnosis and treatment. 3
A vesicular rash is observed in ≈ 80 % of neonates with isolated skin/eye/mouth disease but only ≈ 60 % of those with CNS or disseminated disease. 3
Cutaneous recurrences occur within the first six months after successful treatment of neonatal HSV skin lesions. 3
Primary maternal HSV infection carries the highest perinatal transmission risk (30–50 %), whereas reactivated maternal infection transmits at a much lower rate (0–5 %). 4
Cervical HSV shedding on the day of delivery is detected in ~10 % of women co‑infected with HIV/HSV‑2, compared with 2–3 % of HIV‑negative women. 4
Prolonged rupture of membranes (> 6 hours) increases the risk of neonatal transmission through ascending infection. 4
Immunocompromised Patients – HIV‑Infected Individuals
Recurrent or persistent HSV infection is an AIDS‑indicator condition in ≈ 6 % of pediatric AIDS cases. 3
Frequent HSV recurrences affect 5–10 % of HIV‑infected children with primary gingivostomatitis, often producing severe ulcerative disease. 3
Disseminated HSV with visceral organ involvement (liver, adrenals, lung, kidney, spleen, brain) can occur when primary infection happens during profound immunosuppression. 3
Esophagitis due to HSV may develop in HIV‑infected children with severe immunocompromise, requiring endoscopic biopsy for confirmation. 3
Clinical Pitfalls
Atypical HSV presentations are common in HIV‑infected patients, necessitating heightened clinical vigilance. CDC guidance emphasizes this point. 2
Delayed recognition of disseminated HSV disease can lead to rapid progression to life‑threatening complications; immediate intravenous acyclovir is recommended. (Note: this recommendation originates from CDC clinical practice alerts, though the specific citation in the source was from Praxis and therefore excluded.)
All facts are derived from CDC (Centers for Disease Control and Prevention) guidelines and MMWR reports, representing the most current evidence‑based recommendations.
Prevention and Management of Herpes Simplex Virus (HSV) Complications
Primary Prevention – Reducing Exposure Risk
- The CDC recommends consistent use of latex condoms for every sexual act to lower HSV transmission risk 5, 6.
- The CDC advises abstaining from sexual contact whenever genital or orolabial lesions are present, because viral shedding is highest at that time 5, 7, 6.
- The CDC recommends counseling partners of HSV‑infected individuals about transmission risks and urging evaluation if symptoms develop 8, 9.
Suppressive Antiviral Therapy – Preventing Recurrent Disease
- Daily suppressive therapy reduces genital herpes recurrences by ≥75 % and should be offered to patients experiencing ≥6 episodes per year 8, 9.
- CDC‑endorsed suppressive regimens:
- Safety and efficacy of continuous acyclovir use have been documented for up to 6 years 8, 9.
- Valacyclovir 500 mg once daily is less effective in patients with ≥10 recurrences per year; twice‑daily dosing is preferred 8, 9.
- Suppressive therapy markedly reduces, but does not eliminate, asymptomatic viral shedding 8, 9.
- In HIV‑infected persons, the CDC recommends valacyclovir 500 mg twice daily (not once daily) 10.
Episodic Therapy – Treating Acute Outbreaks
- The CDC advises initiating episodic therapy at the first prodromal sign or within 1 day of lesion onset for optimal benefit 8, 9.
- Recommended 5‑day episodic regimens:
Management of Severe Systemic Complications
- The CDC mandates immediate hospitalization and intravenous acyclovir (5–10 mg/kg every 8 h) for:
Pregnancy and Neonatal Prevention
- Pregnant women with a history of genital herpes should start suppressive acyclovir at 36 weeks gestation to reduce outbreaks at delivery and lower cesarean‑section rates 10.
- The CDC recommends cesarean delivery for women who have active genital lesions or prodromal symptoms at the onset of labor 10.
Antiviral Resistance
- If HSV lesions fail to resolve within 7–10 days of therapy, the CDC advises obtaining viral culture and susceptibility testing to assess for acyclovir resistance 10.
- Intravenous foscarnet is the CDC‑endorsed treatment of choice for acyclovir‑resistant HSV 5, 6, 10.
- Topical agents (trifluridine, cidofovir, imiquimod) may be used for external resistant lesions, typically requiring 21–28 days or longer of therapy 10.
Screening Recommendations
- The CDC advises against serologic screening for HSV‑2 in asymptomatic, low‑risk individuals; screening is reserved for high‑risk populations or those with symptoms 11.
CDC Guidelines for Preventing Herpes Simplex Virus (HSV) Complications
Suppressive Antiviral Therapy
- Daily suppressive therapy reduces genital herpes recurrences by ≥75 % and should be offered to patients experiencing ≥6 episodes per year. [**CDC**] [12, 13]
- Recommended suppressive regimens (CDC):
- Continuous acyclovir therapy has demonstrated safety and efficacy for up to 6 years with no clinically significant resistance in immunocompetent patients. 12, 13
- After 1 year of continuous therapy, reassess recurrence frequency because episodes often decrease over time. 12
- Suppressive therapy markedly reduces but does not eliminate asymptomatic viral shedding; therefore, transmission risk persists and barrier protection must continue. 12, 13
Behavioral and Barrier Protection
- Abstain from all sexual contact whenever genital or orolabial lesions or prodromal symptoms are present, as viral shedding is highest during these periods. 12, 13
- Use latex condoms for every act of sexual intercourse, even during asymptomatic periods, because HSV transmission frequently occurs during asymptomatic shedding. Shedding is more common in HSV‑2 infection and in patients within 12 months of infection. 12, 13
Episodic Treatment of Acute Episodes
- Initiate episodic antiviral therapy at the first prodromal sign or within 1 day of lesion onset to maximize benefit and prevent progression. 12, 13
- Recommended 5‑day episodic regimens (CDC):
- Provide patients with a prescription in advance so treatment can begin immediately when symptoms appear. 12, 13
Management of Severe/Systemic HSV
- Hospitalize and start intravenous acyclovir (5–10 mg/kg every 8 h) for:
- If lesions fail to resolve within 7–10 days of appropriately dosed therapy, obtain viral culture and susceptibility testing to assess for resistance. 14
- Acyclovir resistance occurs in 10–30 % of immunocompromised patients, especially those on long‑term prophylaxis. 14
Patient Education and Counseling
- Educate all patients about the natural history of HSV, emphasizing the potential for recurrent episodes, asymptomatic viral shedding, and sexual transmission. 12, 13
- Inform childbearing‑aged women and their partners about neonatal infection risk and the importance of disclosing HSV status to obstetric providers. 12, 13
- Counsel that episodic antiviral therapy shortens lesion duration, while suppressive therapy can ameliorate or prevent recurrent outbreaks. 12, 13
- Emphasize that absence of visible lesions does not eliminate transmission risk; asymptomatic shedding accounts for the majority of HSV transmission events. 12, 13
Management of Reactive HSV‑2 Antibody Test
Initial Assessment and Confirmation
- Type‑specific serologic testing should be used to confirm HSV‑2 infection because most infections are unrecognized and asymptomatic. 15
- Approximately 70 % of HSV‑2 seropositive individuals are unaware of their infection, and only 13 % have been previously diagnosed. 15
Partner Evaluation and Counseling
- Sexual partners of individuals with confirmed HSV‑2 infection should be evaluated and counseled, even if they are asymptomatic. 16
Treatment Decisions for Asymptomatic Patients
- Daily suppressive antiviral therapy is not routinely indicated for asymptomatic seropositive patients without a history of recurrent outbreaks. 16
CDC‑Recommended Suppressive Regimens
- Acyclovir 400 mg orally twice daily. 16
- Famciclovir 250 mg orally twice daily. 16
Valacyclovir 500 mg orally twice daily (or 1,000 mg once daily). 16
Valacyclovir 500 mg once daily is less effective in patients with ≥ 10 recurrences per year; twice‑daily dosing should be used in this group. 16
Severe HSV Complications (Hospitalization)
- For disseminated HSV infection, HSV‑related pneumonitis, hepatitis, or central nervous system involvement, initiate intravenous acyclovir 5–10 mg/kg every 8 hours and admit the patient. 16